Ra Capital Management, L.P. Astria Therapeutics, Inc. Transaction History
Ra Capital Management, L.P.
- $4.82 Billion
- Q1 2025
A detailed history of Ra Capital Management, L.P. transactions in Astria Therapeutics, Inc. stock. As of the latest transaction made, Ra Capital Management, L.P. holds 5,105,213 shares of ATXS stock, worth $31.8 Million. This represents 0.57% of its overall portfolio holdings.
Number of Shares
5,105,213
Previous 5,105,213
-0.0%
Holding current value
$31.8 Million
Previous $45 Million
39.39%
% of portfolio
0.57%
Previous 0.73%
Shares
5 transactions
Others Institutions Holding ATXS
# of Institutions
116Shares Held
51MCall Options Held
5.3KPut Options Held
6.1K-
Perceptive Advisors LLC New York, NY6.49MShares$40.4 Million1.45% of portfolio
-
Vestal Point Capital, LP New York, NY4.18MShares$26 Million1.59% of portfolio
-
Fcpm Iii Services B.V. Naarden, P73.82MShares$23.8 Million4.93% of portfolio
-
Fairmount Funds Management LLC Philadelphia, PA3.55MShares$22.1 Million6.47% of portfolio
-
Black Rock Inc. New York, NY3.52MShares$21.9 Million0.0% of portfolio
About Astria Therapeutics, Inc.
- Ticker ATXS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 15,178,000
- Market Cap $94.6M
- Description
- Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage...